JP2024532765A - Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療 - Google Patents

Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療 Download PDF

Info

Publication number
JP2024532765A
JP2024532765A JP2024508389A JP2024508389A JP2024532765A JP 2024532765 A JP2024532765 A JP 2024532765A JP 2024508389 A JP2024508389 A JP 2024508389A JP 2024508389 A JP2024508389 A JP 2024508389A JP 2024532765 A JP2024532765 A JP 2024532765A
Authority
JP
Japan
Prior art keywords
compound
pharma
deuterium
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532765A5 (cg-RX-API-DMAC7.html
Inventor
モーガン，アダム・ジェイ
Original Assignee
サン ファーマシューティカル インダストリーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サン ファーマシューティカル インダストリーズ，インコーポレイテッド filed Critical サン ファーマシューティカル インダストリーズ，インコーポレイテッド
Publication of JP2024532765A publication Critical patent/JP2024532765A/ja
Publication of JP2024532765A5 publication Critical patent/JP2024532765A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024508389A 2021-08-12 2022-08-12 Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療 Pending JP2024532765A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232538P 2021-08-12 2021-08-12
US63/232,538 2021-08-12
US202163233059P 2021-08-13 2021-08-13
US63/233,059 2021-08-13
PCT/US2022/040190 WO2023018954A1 (en) 2021-08-12 2022-08-12 Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors

Publications (2)

Publication Number Publication Date
JP2024532765A true JP2024532765A (ja) 2024-09-10
JP2024532765A5 JP2024532765A5 (cg-RX-API-DMAC7.html) 2025-08-19

Family

ID=83188710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508389A Pending JP2024532765A (ja) 2021-08-12 2022-08-12 Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療

Country Status (6)

Country Link
US (1) US20240307401A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384173A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532765A (cg-RX-API-DMAC7.html)
AU (1) AU2022328282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228509A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023018954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116870012A (zh) * 2023-07-26 2023-10-13 北京大学宁波海洋药物研究院 一类甾体硫酸酯化合物在制备jak激酶抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
CN107759601B (zh) * 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
BR112019024509A2 (pt) * 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
CN107915738B (zh) 2017-11-14 2019-07-26 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体2的制备方法
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
EP4172147A1 (en) 2020-06-29 2023-05-03 Concert Pharmaceuticals Inc. Methods and intermediates for preparing jak inhibitors

Also Published As

Publication number Publication date
US20240307401A1 (en) 2024-09-19
CA3228509A1 (en) 2023-02-16
WO2023018954A1 (en) 2023-02-16
AU2022328282A1 (en) 2024-02-22
EP4384173A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
US11945816B2 (en) Inhibitors of EGFR and/or HER2 and methods of use
US11814379B2 (en) Cyano quinoline amide compounds as HER2 inhibitors and methods of use
JP7636388B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用
US20240083934A1 (en) N-acetylgalactosamine (galnac)-derived compounds and oligonucleotides
US9879003B2 (en) Host targeted inhibitors of dengue virus and other viruses
US20100292292A1 (en) Treatment of Neurodegenerative Diseases Using Indatraline Analogs
US11912644B2 (en) Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate
US20110263569A1 (en) Ryanodine channel binders and uses thereof
WO2006034833A1 (en) Cyclic diarly ureas suitable as tyrosine kinase inhibitors
JPS59500130A (ja) 低酸素性腫瘍細胞用ニトロイミダゾ−ル放射線増感剤およびその組成物
WO2008144507A2 (en) Spirooxindole inhibitors of aurora kinase
EP2681198A1 (en) Novel small-molecules as therapeutics
US20240199614A1 (en) Macrocyclic egfr inhibitors for the treatment of cancer
US20240307401A1 (en) Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
AU2022272190A1 (en) Macrocyclic compounds and uses thereof
CN118159271A (zh) 用jak抑制剂的前药治疗jak抑制应答性病症
US9546146B2 (en) Migrastatins and uses thereof
US20190359622A1 (en) Analogs of vincamine and uses thereof
US10273264B2 (en) Cortistatin analogues and syntheses and uses thereof
WO2026089784A2 (en) Compounds and compositions for conjugation to bioligands for imaging and radiopharmaceutical applications
WO2014085791A2 (en) Compositions and uses thereof for treating multiple myeloma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260721